<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680854-A1" country="EP" doc-number="2680854" kind="A1" date="20140108" family-id="45787194" file-reference-id="252638" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586807" ucid="EP-2680854-A1"><document-id><country>EP</country><doc-number>2680854</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12706826-A" is-representative="NO"><document-id mxw-id="PAPP154848999" load-source="docdb" format="epo"><country>EP</country><doc-number>12706826</doc-number><kind>A</kind><date>20120228</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220440200" load-source="docdb" format="original"><country>EP</country><doc-number>12706826.0</doc-number><date>20120228</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140549859" ucid="EP-2012053338-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012053338</doc-number><kind>W</kind><date>20120228</date></document-id></priority-claim><priority-claim mxw-id="PPC140555400" ucid="US-201161448216-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161448216</doc-number><kind>P</kind><date>20110302</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989315766" load-source="docdb">A61P  35/00        20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989318303" load-source="docdb">A61K  31/55        20060101AFI20120921BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-2128527612" load-source="docdb" scheme="CPC">A61K  31/55        20130101 FI20141205BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365054" lang="DE" load-source="patent-office">VERFAHREN ZUR VERABREICHUNG EINES GAMMASEKRETASE-INHIBITORS</invention-title><invention-title mxw-id="PT132365055" lang="EN" load-source="patent-office">METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR</invention-title><invention-title mxw-id="PT132365056" lang="FR" load-source="patent-office">PROCÉDÉ D'ADMINISTRATION D'UN INHIBITEUR DE GAMMA SECRÉTASE</invention-title><citations><non-patent-citations><nplcit><text>See references of WO 2012116975A1</text><sources><source mxw-id="PNPL67456162" load-source="docdb" name="SEA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919510960" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HOFFMANN LA ROCHE</last-name><address><country>CH</country></address></addressbook></applicant><applicant mxw-id="PPAR919544484" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>F.HOFFMANN-LA ROCHE AG</last-name></addressbook></applicant><applicant mxw-id="PPAR919006877" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>F.HOFFMANN-LA ROCHE AG</last-name><iid>100120526</iid><address><street>Grenzacherstrasse 124</street><city>4070 Basel</city><country>CH</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919522607" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>BOYLAN JOHN FREDERICK</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919511620" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>BOYLAN, JOHN FREDERICK</last-name></addressbook></inventor><inventor mxw-id="PPAR919019554" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>BOYLAN, JOHN FREDERICK</last-name><address><street>4 Desiree Court</street><city>Bedminster, New Jersey 07921</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919540302" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>MIKULSKI STANISLAW M</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919545732" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>MIKULSKI, STANISLAW M.</last-name></addressbook></inventor><inventor mxw-id="PPAR919013153" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>MIKULSKI, STANISLAW M.</last-name><address><street>47 Avon Drive</street><city>Essex Fells, New Jersey 07021</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919007456" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Beyermann, Jochen Carl</last-name><iid>101205283</iid><address><street>F. Hoffmann-La Roche AG CLP - Patent Department Grenzacherstrasse 124</street><city>4070 Basel</city><country>CH</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012053338-W"><document-id><country>EP</country><doc-number>2012053338</doc-number><kind>W</kind><date>20120228</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012116975-A1"><document-id><country>WO</country><doc-number>2012116975</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549846770" load-source="docdb">AL</country><country mxw-id="DS549846245" load-source="docdb">AT</country><country mxw-id="DS549846771" load-source="docdb">BE</country><country mxw-id="DS549776500" load-source="docdb">BG</country><country mxw-id="DS549916637" load-source="docdb">CH</country><country mxw-id="DS549844520" load-source="docdb">CY</country><country mxw-id="DS549846250" load-source="docdb">CZ</country><country mxw-id="DS549859768" load-source="docdb">DE</country><country mxw-id="DS549846772" load-source="docdb">DK</country><country mxw-id="DS549844521" load-source="docdb">EE</country><country mxw-id="DS549765034" load-source="docdb">ES</country><country mxw-id="DS549776509" load-source="docdb">FI</country><country mxw-id="DS549776510" load-source="docdb">FR</country><country mxw-id="DS549859769" load-source="docdb">GB</country><country mxw-id="DS549846773" load-source="docdb">GR</country><country mxw-id="DS549846778" load-source="docdb">HR</country><country mxw-id="DS549844526" load-source="docdb">HU</country><country mxw-id="DS549916638" load-source="docdb">IE</country><country mxw-id="DS549846779" load-source="docdb">IS</country><country mxw-id="DS549776511" load-source="docdb">IT</country><country mxw-id="DS549844527" load-source="docdb">LI</country><country mxw-id="DS549859774" load-source="docdb">LT</country><country mxw-id="DS549846251" load-source="docdb">LU</country><country mxw-id="DS549859775" load-source="docdb">LV</country><country mxw-id="DS549859776" load-source="docdb">MC</country><country mxw-id="DS549846252" load-source="docdb">MK</country><country mxw-id="DS549846253" load-source="docdb">MT</country><country mxw-id="DS549765035" load-source="docdb">NL</country><country mxw-id="DS549765424" load-source="docdb">NO</country><country mxw-id="DS549765036" load-source="docdb">PL</country><country mxw-id="DS549776512" load-source="docdb">PT</country><country mxw-id="DS549765041" load-source="docdb">RO</country><country mxw-id="DS549776517" load-source="docdb">RS</country><country mxw-id="DS549765042" load-source="docdb">SE</country><country mxw-id="DS549916639" load-source="docdb">SI</country><country mxw-id="DS549765433" load-source="docdb">SK</country><country mxw-id="DS549765434" load-source="docdb">SM</country><country mxw-id="DS549846258" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99836325" ref-ucid="WO-2012116975-A1" lang="EN" load-source="patent-office"><p num="0000">There are provided new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N- ((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N'-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels.</p></abstract><abstract mxw-id="PA100332097" ref-ucid="WO-2012116975-A1" lang="EN" source="national office" load-source="docdb"><p>There are provided new dosage regimens for the gamma secretase inhibitor 2,2-Dimethyl-N- ((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N'-(2,2,3,3,3-pentafluoro-propyl)-malonamide which maximizes anti-tumor activity while maintaining acceptable toxicity levels.</p></abstract><abstract mxw-id="PA99836326" ref-ucid="WO-2012116975-A1" lang="FR" load-source="patent-office"><p num="0000">L'invention concerne de nouveaux régimes posologiques pour l'inhibiteur de gamma secrétase 2,2-Diméthyl-N- ((S)-6-oxo-6,7-dihydro-5H-dibenzo [b,d]azépin-7-yl)-N'-(2,2,3,3,3-pentafluoro-propyl)-malonamide, qui rendent maximale l'activité anti-tumorale tout en conservant des niveaux de toxicité acceptables.</p></abstract><abstract mxw-id="PA100332098" ref-ucid="WO-2012116975-A1" lang="FR" source="national office" load-source="docdb"><p>L'invention concerne de nouveaux régimes posologiques pour l'inhibiteur de gamma secrétase 2,2-Diméthyl-N- ((S)-6-oxo-6,7-dihydro-5H-dibenzo [b,d]azépin-7-yl)-N'-(2,2,3,3,3-pentafluoro-propyl)-malonamide, qui rendent maximale l'activité anti-tumorale tout en conservant des niveaux de toxicité acceptables.</p></abstract><description mxw-id="PDES51233256" ref-ucid="WO-2012116975-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> METHOD FOR ADMINISTRATION OF A GAMMA SECRETASE INHIBITOR </p><p id="p0002" num="0002">The present invention is directed to improved methods of administration of gamma sectretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N'-(2,2,3,3,3- pentafluoro-propyl)-malonamide (Compound A) in the treatment of cancer. In particular, the invention is directed to improved methods of administration of said "Compound A" that provide desirable antineoplastic effects with a tolerable level toxicity. The methods of the invention are characterized by administering Compound A in a variety of schedules over different days per cycle. Cancer is a disease characterized by uncontrolled proliferation. Advances in understanding the signals that drive cancer are being made. During development and tissue remodeling, pluripotent stem cells serve as the source for differentiating cells to give rise to non-proliferating specialized cell types. A link between the characteristics of these stem cells and the rapid uncontrolled proliferation of tumors is becoming clear. One of the major developmental signaling axes is the Notch pathway. Notch signaling regulates cell-fate by mediating the differentiation of progenitor cells during development and self -renewal of adult pluripotent stem cells. Notch functions to maintain progenitor cells in a pluripotent rapidly proliferating state. The Notch pathway plays an important role in development differentiation and processes of hematopoiesis and lymphopoiesis. It is involved in generation, proliferation and differentiation of </p><p id="p0003" num="0003">hematopoietic stem cells during embryonic development. </p><p id="p0004" num="0004">Notch gene amplification, chromosomal translocation or mutations lead to elevated Notch signaling, thereby imparting a tumor growth advantage by keeping tumor cells in a stem cell-like proliferative state. Therefore, there is a very strong correlation between mutation in the Notch signaling pathway and pathogenesis of malignancies. </p><p id="p0005" num="0005">The Notch proteins, represented by four homologs in mammals (Notchl, Notch2, Notch3, and Notch4), interact with ligands Delta-like 1, Delta-like 3, Delta-like 4, Jagged 1, and Jagged 2. After ligand binding, Notch receptors are activated by serial proteolytic cleavage events 
<!-- EPO <DP n="3"/>-->
 including intramembranous cleavage regulated by γ-secretase. Such a γ-secretase-processed Notch becomes active as a form called 'intracellular Notch' (ICN). The ICN translocates to the nucleus and forms part of a large transcription complex involving the CSL (CBF-1, Suppressor of hairless, Lag) transcriptional regulator directly altering the expression of key proliferation- and differentiation- specific genes. </p><p id="p0006" num="0006">The gamma secretase inhibitor 2,2-Dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin- 7-yl)-N'-(2,2,3,3,3-pentafluoro-propyl)-malonamide (disclosed in WO 2005/023772 as useful for the treatment of Alzheimer's disease) is a water-soluble, orally-administered small molecule antagonist of γ-secretase, a key enzyme in the intramembrane proteolytic processing of several signaling receptors, including Notch, amyloid precursor protein (APP), CD44, and Her4. </p><p id="p0007" num="0007">Blocking Notch signaling via γ-secretase inhibition produces a slower growing, less transformed phenotype in human cancer cells in vivo. The use of Compound A in the treatment of cancer is disclosed in WO 2009/087130. The present invention discloses specific dosage regimen for improved patient compliance, in particular by maintaining the desirable antineoplastic effects of Compound A with a tolerable level toxicity. Therefore, in one embodiment, the present invention relates to a method of treating a patient suffering with cancer, in particular a solid tumor cancer, comprising administering to the patient a compound of the formula </p><p id="p0008" num="0008"><img id="imgf000003_0001" he="40" wi="86" file="imgf000003_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 (A), or a pharmaceutically acceptable salt thereof, following a drug regimen schedule selected from the group consisting of </p><p id="p0009" num="0009">(a) from about 120 mg to about 270 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 3 days-on; 4 days-off; for 2 weeks, q3w, 6 dosing days in a 3 week cycle; 
<!-- EPO <DP n="4"/>-->
 (b) from about 80 mg to about 130 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 7 days-on; 14 days-off; q3w, 7 dosing days in a 3 week cycle; </p><p id="p0010" num="0010">(c) from about 10 mg to about 270 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 1 day-on; I day-off, q3w , 11 dosing days in a 3-week cycle; </p><p id="p0011" num="0011">(d) from about 30 mg to about 1300 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 1 day-on; 6 days-off; q3w, 3 dosing days in a 3 -week cycle; (e) from about 10 mg to about 600 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 1 day-on; 2 days-off; then 1 day-on; 3 days-off; q3w,6 dosing days in a 3 week cycle; and </p><p id="p0012" num="0012">(f) from about 5 mg to about 400 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 5 days-on; 2 days-off; q3w, 15 dosing days in a 3-week cycle. </p><p id="p0013" num="0013">In another embodiment, the present invention relates to Compound A for use in the treatment of cancer, characterized by administering Compound A according to the dosage regimen (a) to (f) as disclosed above. </p><p id="p0014" num="0014">In still another embodiment, the present invention relates to the use of Compound A for the manufacture of medicaments for the treatment of cancer, characterized in that said Compound A is administered according to any of the dosage regimen (a) to (f) as disclosed above. In yet another embodiment of the present invention, the cancer is a solid tumor, such as for example non-small cell lung cancer, breast cancer in its various subtypes, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, various sarcomas and primary brain tumors. </p><p id="p0015" num="0015">Detailed Description of the Invention </p><p id="p0016" num="0016">As used herein, the term "Compound A ", or "compound of formula (A)", shall refer to 2,2- dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N'-(2,2,3,3,3-pentafluoro- propyl)-malonamide or a pharmaceutically acceptable salt thereof. The compound has the following structure: 
<!-- EPO <DP n="5"/>-->
 
<img id="imgf000005_0001" he="38" wi="92" file="imgf000005_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0017" num="0017">As used herein, the term "anti-neoplastic" means inhibiting or preventing the development, maturation or proliferation of malignant cells. </p><p id="p0018" num="0018">The term "therapeutically effective" means an amount of drug, or combination or composition, which is effective for producing a desired therapeutic effect upon administration to a patient, for example, to stem the growth, or result in the shrinkage, of a cancerous tumor. The term "q3w" means every 3 weeks. </p><p id="p0019" num="0019">"Therapeutic index" is a well-recognized term of art and is an important parameter in the selection of anticancer agents for clinical trial. Therapeutic Index takes into consideration the efficacy, pharmacokinetics, metabolism and bioavailability of anticancer agents. See, e.g., J. Natl. Cancer Inst. 81(13): 988-94 (July 5, 1989). </p><p id="p0020" num="0020">The term "pharmaceutically acceptable," such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of the present invention and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Sample base-addition salts include those derived from ammonium, potassium, sodium, and quaternary ammonium hydroxides, such as for example, tetramethylammonium hydroxide. The term "pharmaceutically acceptable ester" of a compound means a conventionally esterified compound having a carboxyl group, which 
<!-- EPO <DP n="6"/>-->
 esters retain the biological effectiveness and properties of the compound. Chemical modification of a pharmaceutical compound (i.e., drug) into a salt is a technique well known to </p><p id="p0021" num="0021">pharmaceutical chemists to obtain improved physical and chemical stability, hydroscopicity, and solubility of compounds. See, e.g., H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6<sup>th</sup> Ed. 1995) at pp. 196 and 1456-1457. </p><p id="p0022" num="0022">The term "tumor control" means that the size of the tumor has either decreased, or has not increased by the defined and generally accepted criteria: e.g., the sum of the longest dimensions of the measurable tumor lesions has not increased by 20% or more as compared with the baseline, or with the shortest dimension of that lesion achieved post-treatment (RECIST =</p><p id="p0023" num="0023">Response Evaluation Criteria in Solid Tumors, rules 1.1 published January 2009), or for specific tumor lesions such as those related to lymphoma and/or intracranial metastases of solid tumors, the sum of the products of the perpendicular diameters of measurable lesions has not increased by 25% or more from the baseline or from the last measurement. (See, e.g. , World Health Organization ("WHO") Handbook for Reporting Results of Cancer Treatment, Geneva (1979). </p><p id="p0024" num="0024">In certain instances, the criteria for the volumetric (three-dimensional = 3D) tumor </p><p id="p0025" num="0025">measurements might be applied (e.g., for the brain metastatic lesions). "Tumor volume (in cubic millimeter)" for purposes of measuring tumor size is calculated using the ellipsoid formula: </p><p id="p0026" num="0026"> (D x (d<sup>2</sup>))/2 </p><p id="p0027" num="0027">where "D" represents the large diameter of the tumor, and "d" represents the small diameter. The term "autoinduction" shall mean a promotion of the compound' s own metabolism by Compound A inducing the activity of the relevant CYP450 metabolizing enzyme(s). </p><p id="p0028" num="0028">In the first two embodiments of the invention, the 3-4 schedule (3 days-on; 4 days-off; for 2 weeks, q3w) (A) and the 7-14 schedule (7 days-on; 14 days-off; q3w) (B) both contain rest weeks in the 3-week cycle. This will enable the collection of PD data using these two schedules. These two schedules (A and B) include 6 and 7 dosing days in a 3-week cycle, respectively. </p><p id="p0029" num="0029">In yet another embodiment of the invention, the 1- 1 schedule (1 day-on; I day-off q3w) </p><p id="p0030" num="0030">(schedule C) provides a simple schedule and is relevant considering that the mean terminal half- 
<!-- EPO <DP n="7"/>-->
 life defined thus far in an ongoing first phase I trial of Compound A is reported to be 42.2 hours (range between 10 to 93 hours). This schedule (C) includes 11 dosing days in a 3-week cycle. </p><p id="p0031" num="0031">In another embodiment of the invention the 1-6 schedule (1 day-on; 6 days-off; q3w) (schedule D) will assess the relevance of a weekly administration of Compound A. Because it does not include any consecutive dosings, this simple regimen should minimize the risk of autoinduction. Moreover, it should allow assessment of maximal concentration (Cmax) effect on toxicity and efficacy. It incorporates 3 dosing days in a 3 -week cycle. In another embodiment of the invention the 1-2-1-3 schedule (1 day-on; 2 days-off; then 1 day- on; 3 days-off; q3w) (schedule E) represents an intermediate intermittent regimen between the 1- 6 schedule and the 1-1 schedule. It integrates Compound A administration twice a week to limit the risk of autoinduction while increasing systemic exposure with respect to the 1-6 schedule. It includes 6 dosing days in a 3-week cycle. </p><p id="p0032" num="0032">In another embodiment of the invention the 5-2 schedule (5 days-on; 2 days-off; q3w) (schedule F) represents the most dose intense schedule to be tested in this study. In this schedule (F), patients are to be dosed for 5 consecutive days with 2 days off each week, without any rest weeks. It comes close to a continuous administration schedule which was investigated with success in a preclinical model (Teachey, Seif et al. 2008). Moreover, it will allow assessment of safety of a regimen that could be used concomitantly with radiation treatment. It includes 15 dosing days in a 3-week cycle. </p><p id="p0033" num="0033">Although the different schedule schedules (A to F) include an increasing numbers of dosing days (from 3 to 15 dosing days in a 3-week cycle), the initial drug doses will be adapted so that the dose intensity of Compound A given in a 3-week cycle does not exceed the one offered by the 3- 4 schedule at the highest safe dose tested so far (270 mg/day * 6 dosing days every 3 weeks in 3- 4 schedule). If deemed safe, then dose escalation to dose intensities at and above that given in the 3-4 schedule at 270 mg/day will be performed. For safety reasons, the first cohorts of patients enrolled in schedules C, D, E and F will be treated with lower doses (dose level 1: 14% to 37 % of dose intensity of 3-4 schedule at 270 mg). Then in the subsequent cohorts, the dose will be escalated by 50%- 100%. </p><p id="p0034" num="0034">The invention is now illustrated by the following Examples, which are in no way meant to limit the scope of the present claims. 
<!-- EPO <DP n="8"/>-->
 Examples </p><p id="p0035" num="0035">The objective of experiment 1 in the table of Example 1 was to compare six new dosing schedules of Compound A with different clinical schedules at different dose levels and determine treatment safety, efficacy, PK and PD parameters. </p><p id="p0036" num="0036">Example 1 </p><p id="p0037" num="0037">Table 1. Schedules of administration and drug dose levels </p><p id="p0038" num="0038"><img id="imgf000008_0001" he="121" wi="167" file="imgf000008_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0039" num="0039"> *More patients may be added as necessary. </p><p id="p0040" num="0040">In the above clinical trial, the safety, efficacy, PK and PD parameters of six intermittent administration schedules of Compound A are investigated. </p><p id="p0041" num="0041">Patients enrolled in the above studies have a variety of tumors including solid tumors such as, non-small cell lung cancer, various subtypes of breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, various sarcomas and primary brain tumors. Also patients with blood cancer such as leukemia are included 
</p></description><claims mxw-id="PCLM125309646" ref-ucid="WO-2012116975-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="9"/>--> Claims </claim-statement><claim id="clm-0001" num="1"><claim-text>1. The compound of the formula </claim-text><claim-text><img id="imgf000009_0001" he="45" wi="108" file="imgf000009_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, characterized by administering said compound (A) according to a regimen selected from the group consisting of </claim-text><claim-text>(a) from about 120 mg to about 270 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 3 days-on; 4 days-off; for 2 weeks, q3w, 6 dosing days in a 3 week cycle; (b) from about 80 mg to about 130 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 7 days-on; 14 days-off; q3w, 7 dosing days in a 3 week cycle; </claim-text><claim-text>(c) from about 10 mg to about 270 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 1 day-on; I day-off, q3w , 11 dosing days in a 3-week cycle; </claim-text><claim-text>(d) from about 30 mg to about 1300 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 1 day-on; 6 days-off; q3w, 3 dosing days in a 3-week cycle; </claim-text><claim-text>(e) from about 10 mg to about 600 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 1 day-on; 2 days-off; then 1 day-on; 3 days-off; q3w,6 dosing days in a 3 week cycle; and </claim-text><claim-text>(f) from about 5 mg to about 400 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 5 days-on; 2 days-off; q3w, 15 dosing days in a 3 -week cycle. 
<!-- EPO <DP n="10"/>-->
</claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The compound (A) for the use according to claim 1, characterized in that said compound (A) is administered from about 120 mg to about 270 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 3 days-on; 4 days-off; for 2 weeks, q3w, 6 dosing days in a 3 week cycle. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The compound (A) for use according to claim 1, characterized in that said compound (A) is administered from about 80 mg to about 130 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 7 days-on; 14 days-off; q3w, 7 dosing days in a 3 week cycle. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The compound (A) for use according to claim 1, characterized in that said compound (A) is administered from about 10 mg to about 270 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 1 day-on; I day-off, q3w , 11 dosing days in a 3- week cycle. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The compound (A) for use according to claim 1, characterized in that said compound (A) is administered from about 30 mg to about 1300 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 1 day-on; 6 days-off; q3w, 3 dosing days in a 3- week cycle. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The compound (A) for use according to claim 1, characterized in that said compound (A) is administered from about 10 mg to about 600 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 1 day-on; 2 days-off; then 1 day-on; 3 days-off; q3w, 6 dosing days in a 3 week cycle. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The compound (A) for use according to claim 1, characterized in that said compound (A) is administered from about 5 mg to about 400 mg of the compound of formula (A), or a pharmaceutically acceptable salt thereof, for 5 days-on; 2 days-off; q3w, 15 dosing days in a 3- week cycle. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The compound (A) for use according to any one of claims 1 to 7, wherein the cancer is a solid tumor. 
</claim-text></claim><claim id="clm-0009" num="9"><claim-text><!-- EPO <DP n="11"/>-->
 The use of the compound of formula </claim-text><claim-text><img id="imgf000011_0001" he="45" wi="108" file="imgf000011_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 or a pharmaceutically acceptable salt thereof, in the manufacture of medicaments for the treatment of cancer, characterized by dosing said compound (A) according to a dosage regimen selected from </claim-text><claim-text>(a) from about 120 mg to about 270 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 3 days-on; 4 days-off; for 2 weeks, q3w, 6 dosing days in a 3 week cycle; or </claim-text><claim-text>(b) from about 80 mg to about 130 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 7 days-on; 14 days-off; q3w, 7 dosing days in a 3 week cycle; or </claim-text><claim-text>(c) from about 10 mg to about 270 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 1 day-on; I day-off, q3w , 11 dosing days in a 3-week cycle; or </claim-text><claim-text>(d) from about 30 mg to about 1300 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 1 day-on; 6 days-off; q3w, 3 dosing days in a 3-week cycle; or </claim-text><claim-text>(e) from about 10 mg to about 600 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 1 day-on; 2 days-off; then 1 day-on; 3 days-off; q3w,6 dosing days in a 3 week cycle; or </claim-text><claim-text>(f) from about 5 mg to about 400 mg of the compound of formula (A) or a pharmaceutically acceptable salt thereof for 5 days-on; 2 days-off; q3w, 15 dosing days in a 3 -week cycle. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The use according to claim 9, wherein the cancer is a solid tumor. 
<!-- EPO <DP n="12"/>-->
</claim-text></claim><claim id="clm-0011" num="11"><claim-text>1. The novel methods, compositions and uses substantially as disclosed herein. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
